Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arch Immunol Ther Exp (Warsz) ; 59(4): 239-47, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21644029

RESUMO

Infection with Shiga toxin (Stx)-producing Escherichia coli (STEC), including O157:H7, causes bloody diarrhea and hemorrhagic colitis in humans, occasionally resulting in fatal systemic complications, such as neurological damage and hemolytic-uremic syndrome. Because Stx is a major virulence factor of the infectious disease, a series of Shiga toxin neutralizers with various structural characteristics has been developed as promising therapeutic agents. Most of these agents function to bind to the toxin directly and inhibit the binding to its receptor present on the target cells. Other neutralizers do not inhibit receptor binding but induce aberrant intracellular transport of the toxin, resulting in effective detoxification. Such a novel type of Stx neutralizer provides a new therapeutic strategy against STEC infections. Here, recent progress of the development of Stx neutralizers is reviewed.


Assuntos
Antibacterianos/química , Infecções por Escherichia coli/tratamento farmacológico , Peptídeos/administração & dosagem , Toxina Shiga I/antagonistas & inibidores , Toxina Shiga II/antagonistas & inibidores , Triexosilceramidas/administração & dosagem , Animais , Antibacterianos/uso terapêutico , Sítios de Ligação/efeitos dos fármacos , Técnicas de Química Combinatória/métodos , Desenho de Fármacos , Retículo Endoplasmático/metabolismo , Escherichia coli O157/metabolismo , Globosídeos/metabolismo , Síndrome Hemolítico-Urêmica/microbiologia , Humanos , Macrófagos Peritoneais/metabolismo , Camundongos , Peptídeos/síntese química , Polímeros/farmacologia , Polímeros/uso terapêutico , Coelhos , Componente Amiloide P Sérico/metabolismo , Componente Amiloide P Sérico/uso terapêutico , Toxina Shiga I/química , Toxina Shiga II/química , Silanos/síntese química , Silanos/uso terapêutico , Trissacarídeos/síntese química , Trissacarídeos/uso terapêutico , Fatores de Virulência/metabolismo
2.
J Infect Dis ; 194(8): 1135-40, 2006 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-16991089

RESUMO

Fabry disease is an X-linked recessive disorder in which affected persons lack alpha-galactosidase A (alpha -GalA), which leads to excess glycosphingolipids in tissues, mainly globotriaosylceramide (Gb3). Gb3 is the cellular receptor for Shiga toxin (Stx), the primary virulence factor of enterohemorrhagic Escherichia coli. alpha-GalA-knockout mice were significantly protected against lethal intraperitoneal doses of Stx2 or oral doses of Stx2-expressing bacteria, compared with wild-type (wt) control mice. Kidneys of moribund wt mice revealed tubular necrosis, but no histopathologic changes were observed in Gb3-overexpressing mice. Reducing Gb3 levels in alpha-GalA-knockout mice by the intravenous injection of recombinant human alpha-GalA restored the susceptibility of knockout mice to lethal doses of Stx2. These results suggest that excess amounts of Gb3 in alpha-GalA-deficient mice may impair toxin delivery to susceptible tissues.


Assuntos
Infecções por Escherichia coli/patologia , Escherichia coli O157/metabolismo , Doença de Fabry , Rim/patologia , Toxinas Shiga/toxicidade , Administração Oral , Animais , Feminino , Injeções Intraperitoneais , Masculino , Camundongos , Camundongos Knockout , Toxinas Shiga/administração & dosagem , Triexosilceramidas/administração & dosagem , Triexosilceramidas/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...